LLY Feb 2025 670.000 put
| Previous close | 19.85 |
| Open | 19.85 |
| Bid | 0.00 |
| Ask | 0.00 |
| Strike | 670.00 |
| Expiry date | 2025-02-21 |
| Day's range | 19.85 - 19.85 |
| Contract range | N/A |
| Volume | |
| Open interest | 6 |
Barrons.comThese Stocks Are Moving the Most Today: Apple, Meta, Trump Media, RXO, Eli Lilly, ResMed, Under Armour, and More
Apple is charged by the European Union for failing to comply with the Digital Markets Act, while separately, a report says the iPhone maker is talking with Meta Platforms about an artificial-intelligence partnership. Trump Media rises as it expects proceeds of nearly $70 million from the exercise of warrants last week.
Insider MonkeyDid Eli Lilly and Company (LLY) Achieve Its 10th Consecutive Year of Dividend Growth?
We recently compiled a list of the 10 Dividend Zombies and Kings with Longest Dividend Payouts. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other dividend stocks. Last year, artificial intelligence (AI) was the main focus in the markets, driving tech stocks to […]
PR NewswireLilly's tirzepatide reduced obstructive sleep apnea (OSA) severity, with up to 51.5% of participants meeting the criteria for disease resolution
Eli Lilly and Company (NYSE: LLY) announced detailed results from the SURMOUNT-OSA phase 3 clinical trials evaluating tirzepatide injection (10 mg or 15 mg) for the treatment of moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity, with and without positive airway pressure (PAP) therapy. In both studies, tirzepatide achieved all primary and key secondary endpoints for both the efficacyi and treatment-regimenii estimands and demonstrated a mean reduction of up to 62.8% on the a
